Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical study on individualized and precise immunotherapy for colorectal cancer based on high-throughput tumor antigen polypeptides screening

ABSTRACT: Interventions: therapy group:Individualized and precise immunotherapy for colorectal cancer based on high-throughput tumor antigen polypeptides screening Primary outcome(s): Incidence of adverse events;Progression free survival Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2705817 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Clinical study on diagnosis of colorectal cancer based on high-throughput tumor antigen polypeptides screening

Project description:Interventions: Gold Standard:Pathological diagnosis;Index test:high-throughput tumor antigen polypeptides screening Primary outcome(s): Diagnostic accuracy Study Design: Factorial

| 2704426 | ecrin-mdr-crc

A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients

Project description:Molecular targeted therapy has shown potential in hepatocellular carcinoma (HCC) patients, and immunotherapy applications are developing rapidly. However, clinical guidance for making individualized therapy decisions for HCC patients remains lacking. To facilitate individualized and reasonable clinical guidance for each HCC patient, we constructed the MDH score.

2022-09-22 | GSE213615 | GEO

Establishment of Individualized Immunotherapy Strategy and Platform Based on Changes of Intestinal Microbiota

Project description:To explore and analyze the relationship between intestinal flora changes and the efficacy of individualized immunotherapy in patients with upper gastrointestinal cancer, and to find new biomarkers to predict the efficacy of immunotherapy, bringing new breakthroughs in tumor diagnosis and treatment.

| 2391273 | ecrin-mdr-crc

Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents

Project description:Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents

| PRJNA715188 | ENA

Cytokine-armored dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Project description:Cytokine-armored dendritic cell progenitors for antigen-agnostic cancer immunotherapy

| PRJNA948418 | ENA

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [mouse]

Project description:Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [mouse]

| PRJNA892626 | ENA

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [human]

Project description:Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [human]

| PRJNA894212 | ENA

Intracellular expression of a chimeric antigen reverses resistance to cancer immunotherapy

Project description:Intracellular expression of a chimeric antigen reverses resistance to cancer immunotherapy

| PRJNA1029646 | ENA

Optimizing High-Throughput Shotgun Immunoproteomics for Antigen Identification

Project description:Identification of individual proteins (i.e., antigens) which initiate and/or perpetuate adaptive immune responses has potential to greatly impact pre-clinical and clinical work across numerous fields. To date, however, the methodologies available to identify antigens responsible for driving adaptive immune responses have been plagued by numerous issues which have drastically limited their widespread adoption. Therefore, in this study, we sought to optimize a shotgun immunoproteomics approach to alleviate these persistent issues and create a high-throughput, quantitative methodology for antigen identification. Three individual components of a previously published approach, namely the protein extraction, antigen elution, and LC-MS/MS analysis steps, were optimized in a systematic manner. These studies determined that preparation of protein extracts using a one-step tissue disruption method in immunoprecipitation (IP) buffer, eluting antigens from affinity chromatography columns with 1% trifluoroacetic acid (TFA), and TMT-labeling & multiplexing equal volumes of eluted samples for LC-MS/MS analysis, resulted in quantitative longitudinal antigen identification, with reduced variability between replicates and increased total number of antigens identified. This optimized pipeline provides a multiplexed, highly reproducible, and fully quantitative approach to antigen identification which is broadly applicable to determine the role of antigenic proteins in inciting (i.e. primary antigens) and perpetuating (i.e., secondary antigens) a wide range of diseases.

2023-04-18 | PXD038761 | Pride

Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds

Project description:Immune checkpoint blockade (ICB) therapy intends to only benefit a fraction of cancer patients, and combination immunotherapy with a compound is a promising treatment to overcome this limitation. Here, a tumor immunological phenotype (TIP) gene signature and high throughput sequencing-based high throughput screening (HTS2) were combined to identify combination immunotherapy compounds. We firstly defined a TIP gene signature, which expression pattern distinguishes “cold” tumors from “hot” tumors, and predicts ICB response in cancer patients. Then, after screening thousands of compounds, we identified that aurora kinase inhibitors, including ENMD-2076 and TAK-901, could reprogram the expression pattern of TIP genes from “cold” tumor to “hot” tumor in triple negative breast cancer (TNBC) cells. The treatment of aurora kinase inhibitors on TNBC cells dramatically up-regulates expression of Th1 type chemokine genes CXCL10 and CXCL11, which promotes effective T cells infiltrating into tumor microenvironment and significantly improves anti-PD-1 efficacy in inhibiting the tumor growth of TNBC in preclinical models. Mechanistically, these aurora kinase inhibitors are mainly through inhibiting AURKA-STAT3 signaling pathway to stimulate the expression of CXCL10 and CXCL11. Our study established a high throughput strategy to discover candidate compounds for combination immunotherapy, and suggested the therapeutic potential of combining aurora kinase inhibitors with checkpoint blockade immunotherapy for the treatment of TNBC.

2020-12-31 | GSE160071 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data